2. Academic Validation
  3. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies

Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies

  • Clin Sci (Lond). 2002 Aug;103 Suppl 48:107S-111S. doi: 10.1042/CS103S107S.
J Ruth Wu-Wong 1,  Douglas B Dixon,  William J Chiou,  Brian K Sorensen,  Gang Liu,  H-S Jae,  Andrew Tasker,  Thomas W von Geldern,  Martin Winn,  Terry J Opgenorth
Affiliations

Affiliation

  • 1 Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064, U.S.A. ruth.r.wuwong@abbott.com
PMID: 12193066 DOI: 10.1042/CS103S107S
Abstract

Endothelins (ETs), 21-amino-acid Peptides involved in the pathogenesis of various diseases, bind to ET(A) and ET(B) receptors to initiate their effects. Based on the same core structure, we have developed four small-molecule ET receptor antagonists, ABT-627, ABT-546, A-182086 and A-192621, which exhibit difference in selectivity for ET(A) and ET(B) receptors. In this report, we compare the potency and selectivity of these four antagonists in inhibiting (125)I-labelled ET-1 binding to cloned human ET(A) and ET(B) receptors, and in blocking ET-1-induced functional responses (arachidonic acid release and phosphatidylinositol hydrolysis).

Figures
Products